Latest report from commercetools reveals systemic challenges undermining modernization, and how leading companies are responding New research from commercetools uncovers “The 52% Problem,” a critical issue threatening the growth and resilience of B2B enterprises: more than half are simultaneously grappling with inefficient manual processes, aging technology stacks nearing their end-of-life, and sidelined financial leaders in […]

Trading Technologies International, Inc. (TT), a global capital markets technology platform services provider, today announced that Thoma Bravo, a leading software investment firm, and TT's current owner, 7RIDGE, a specialized growth equity firm invested in transformative technologies for financial services, have agreed to partner for the next phase of TT's growth. This follows a comprehensive

Emerald Clinical Trials, a leading global clinical research organization, today announced a leadership transition. MaryGunn has stepped down effective immediately.The Board has appointed Glenn Kerkhof, a long-standing Board member and experienced CRO executive, as Interim CEO. https://mma.prnewswire.com/media/2657673/George_Clinical__Emerald_Clinical_Trials__logo.jpg The Board has commenced a formal search for a permanent CEO and has asked Glenn Kerkhof to lead

Federal Signal Corporation (NYSE:FSS) (the “Company”), a leader in environmental and safety solutions, today reported financial results for the second quarter ended June30, 2025. Second Quarter Highlights — Net sales of $565 million, up $74 million, or 15%, from last year; organic growth of $42 million, or 9% — Operating income of $97.7 million, up

SEPHIENCE is an FDA-approved oral therapy for the treatment of phenylketonuria (PKU) Orsini, a leader in rare disease pharmacy solutions, has been chosen by PTC Therapeutics as a specialty pharmacy partner for SEPHIENCE™ (sepiapterin), an FDA-approved oral therapy indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and

Emerald Clinical Trials, a leading global clinical research organization, today announced a leadership transition. MaryGunn has stepped down effective immediately.The Board has appointed Glenn Kerkhof, a long-standing Board member and experienced CRO executive, as Interim CEO. https://mma.prnewswire.com/media/2657673/5437419/George_Clinical__Emerald_Clinical_Trials__logo.jpg The Board has commenced a formal search for a permanent CEO and has asked Glenn Kerkhof to lead

Parex Resources Announces Second Quarter Results, Declaration of Q3 2025 Dividend, and Operational Update GlobeNewswire July 30, 2025 CALGARY, Alberta, July 30, 2025 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce its financial and operating results for the three-month period ended June 30, 2025, the declaration of

— Patent covers a method of targeted drug delivery to the brain and central nervous system via subregions of the intranasal cavity — Builds on recent corporate milestones and sets the stage for future strategic partnerships — Advances Rocket Science Health's progression towards broader clinical applications Rocket Science Health Corp., a Canadian healthcare technology company

— Scemblix® is first to show superior efficacy and a favourable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies1,2 — Fifty percent of CML patients do not meet efficacy milestones (MMR) with current SoC and almost 25% discontinue or switch therapies within one year of treatments2 —

Cheer Holding Reports 2025 Half Year Results GlobeNewswire July 30, 2025 BEIJING, July 30, 2025 (GLOBE NEWSWIRE) — Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding” or the “Company”), a leading provider of advanced mobile internet infrastructure and platform services, today announced its financial results for the six months ended June 30, 2025. Financial Highlights for